Pieris Pharmaceuticals, Inc.
PIRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.02 | 0.07 | 3.34 |
| FCF Yield | -35.81% | -329.38% | -79.04% | -3.53% |
| EV / EBITDA | 0.00 | 0.04 | -1.69 | -3.23 |
| Quality | ||||
| ROIC | 0.00% | -111.20% | -68.32% | -47.23% |
| Gross Margin | 0.00% | 2.36% | 89.27% | 92.46% |
| Cash Conversion Ratio | 1.79 | 2.19 | 1.80 | 0.17 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 10.86% | -4.05% | -12.11% |
| Free Cash Flow Growth | 79.92% | 11.45% | -608.25% | 82.29% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.76 | 0.84 | 2.40 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -24.57 | -463.53 | -1,288.49 |